Efficacy of targeted therapy (TT) after checkpoint inhibitors (CPI) in metastatic renal cell carcinoma (mRCC): Results from the Canadian Kidney Cancer Information System (CKCis).
Austin Kalirai(University of Alberta), Naveen S. Basappa, Aly‐Khan A. Lalani(Juravinski Cancer Centre), Eric Winquist(Western University), Denis Soulières(Centre Hospitalier de l’Université de Montréal), Sunita Ghosh(Tata Memorial Hospital), Marco Iafolla(University of Alberta), Lori Wood(Dalhousie University), Vincent Castonguay(Centre hospitalier universitaire de Québec), Christian Kollmannsberger(BC Cancer Agency), Dominick Bossé(Dana-Farber Cancer Institute), Daniel Yick Chin Heng(University of Calgary), Anil Kapoor(People’s University)
Cited by 3
Related Papers
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
|New England Journal of Medicine|2007|1.7k